Introduction
Cytogenetic aberrations are important prognostic factors in acute myeloid leukemia (AML). On the basis of cytogenetic abnormalities, cases of AML are usually classified into three groups, with favorable, intermediate and adverse prognosis. 1 The largest of these is the 'intermediate' group, within which patients with normal karyotype constitute about 45% of cases with de novo AML.
2,3 AML with normal karyotype is a heterogeneous group in which some patients rapidly relapse while others go into complete remission (CR) and currently attempts are being made to distinguish different prognostic subgroups. During the last few years, mutations in the FLT3 (fms-related tyrosine kinase 3) and NPM1 (nucleophosmin) genes have been described and they have become established markers of clinical outcome and survival in cases of de novo AML with normal karyotype. 4, 5 Internal tandem duplication (ITD) within FLT3 occurs in approximately 30% of all cases of AML with normal karyotype and it correlates with poor outcome, whereas absence of this mutation in the presence of NPM1 mutation is associated with favorable prognosis. [4] [5] [6] [7] However, there is still a large group of patients with normal karyotype with intermediate risk who lack reliable prognostic markers and it is obvious from the clinical setting that there is a need for further markers to guide treatment decisions. The development of multi-drug resistance during cancer chemotherapy is a clinically relevant obstacle to successful treatment of AML. Increased expression of P-glycoprotein encoded by the ABCB1 gene is a well-characterized mechanism by which cancer cells in culture avoid the action of chemotherapeutic agents. P-glycoprotein is capable of extruding cytotoxic drugs with different chemical structures and mechanisms of action, such as anthracyclines, vinca alkaloids and epipodophyllotoxins. All of these are used in the treatment of AML and cross-resistance occurs. 8, 9 The activity of P-glycoprotein has also been shown to affect the absorption and the elimination of several drugs. 10, 11 Interestingly, several single-nucleotide polymorphisms (SNPs) in the ABCB1 gene have been identified, of which C1236T (silent), G2677T/A (Ala893Ser/Thr) and C3435T (silent) have been associated with altered P-glycoprotein expression and phenotype. [12] [13] [14] Altered transport activity due to the different genetic variants might lead to reduced capacity for the cells to avoid potential harmful xenobiotics including the cytotoxicity of chemotherapeutic drugs. The SNPs in ABCB1 have also been associated with susceptibility to cancer, altered pharmacokinetics and treatment response to several drugs, including anticancer agents. [15] [16] [17] Both FLT3 and ABCB1 are important for chemoresistance in AML, 18 and NPM1 and FLT3 status have recently become useful prognostic markers. Several studies have addressed the importance of genetic variants of ABCB1 in the treatment of AML, with varying results. [19] [20] [21] [22] However, no study has yet attempted to take both these resistance mechanisms into account, especially not in patients with normal karyotype. We therefore investigated the importance of five different ABCB1 SNPs (that is, G1199A, C1236T, A1308T, G2677T/A and C3435T), FLT3-ITD and NPM1 mutation status for the response and overall survival in 100 de novo AML patients with normal karyotype. We also determined the relevance of the ABCB1 SNPs on AML susceptibility and on the in vitro drug cytotoxicity on isolated leukemic cells from the AML patients.
Materials and methods

Patients
Peripheral blood samples were collected at diagnosis from 100 adult patients (mean age 63, range 20-85) with de novo AML and normal karyotype. No cases of relapsing or secondary leukemia were included. The patients were treated according to national guidelines 23 at Linköping University Hospital and Karolinska University Hospital in Huddinge, Sweden. All but four patients were treated with regimes that included anthracyclines or mitoxantrone in combination with cytarabine and the patients were evaluated up until 4 years. Patient characteristics and details of the induction treatment regime are presented in Table 1 .
The response after chemotherapy was evaluated as non-CR or morphologic CR. 24 To get a more specific effect of the chemotherapy on the survival, patients treated by means of allogeneic bone marrow transplantation (n ¼ 21) were censored at the time of transplantation in the survival analysis.
A Swedish reference material of 400 healthy volunteers of comparable age (median 60, range 22-77) and sex distribution (51% male and 49% female) was also included for the evaluation of ABCB1 genotype susceptibility to develop AML. DNA samples were obtained from a regional DNA bank consisting of genomic DNA isolated from selected individuals representing the population in the southeastern part of Sweden after obtaining their informed consent.
The study was approved by the local ethical committee and all patients included gave their written informed consent for genetic analysis for evaluation of therapeutic efficacy.
ABCB1, NPM1 and FLT3-ITD genotyping The ABCB1 G1199A, C1236T, A1308T, G2677T/A and C3435T genotypes were determined using pyrosequencing as previously described. 25, 26 In short, genomic DNA was isolated using QIAamp DNA mini-kits (Qiagen, Stockholm, Sweden) according to the manufacturer's protocol. HotStarTaq master mixture (VWR International, Stockholm, Sweden) was used for PCR amplification and all reactions were carried out on a Mastercycler gradient instrument (Eppendorf, Hamburg, Germany) in a total volume of 25 ml. The SNPs were analyzed by a Pyrosequencing PSQ96MA instrument (Qiagen) according to the manufacturer's protocol and Abbreviation: G-CSF, granulocyte-colony stimulating factor.
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H Gréen et al as previously described. 25, 26 Insertion mutations in exon 12 of the NPM1 (Gene ID: 4869) gene were detected by fragment analysis of PCR products as described previously. 27 For analysis of FLT3-ITD (FLT3 Gene ID: 2322), PCR and fragment analysis were performed as detailed earlier. 28 In vitro cytotoxicity assay Leukemic cells were isolated by centrifugation on metrizoate-dextran (Lymphoprep, Axis-Shield PoC, Oslo, Norway) from patients being treated at the Karolinska University Hospital (n ¼ 56). The cells, 490% pure as assessed by light microscopy, were incubated and cultured for 4 days with a panel of cytotoxic drugs, as previously described. 29 The drug concentrations were as follows: Ara-C 0.5 mM, daunorubicin 0.2 mM, etoposide 20 mM, mitoxantrone 0.1 mM. All incubations were performed in duplicate and with a drug-free control. Incubations with conventional chemotherapeutic drugs were designed to mimic the in vivo situation. 30 After incubation, cytotoxicity was assessed by means of a bioluminescence method, measuring the intracellular adenosine triphosphate concentration as a marker of cell viability after drug exposure. 29 The cell survival was expressed as percentage of viable cells compared with the control.
Statistical analysis
For comparison of genotype and allele distribution between patients and the reference material, as well as between CR and non-CR, the generalized Fisher's exact test was used. Kaplan-Meier analysis was applied to estimate overall survival and the log-rank test to determine significance. Multivariate analysis was performed using the Cox regression model. Survival was evaluated as number of days after the date of diagnosis until death, the latest follow-up date or allogeneic bone marrow transplantation. When comparing groups in terms of differences in sensitivity in the in vitro drug panel, two-sided non-equal-variance Student's t-test was used. P-values of o5% (Po0.05) were taken as statistically significant. Results are presented as means and 95% confidence intervals.
Results
No difference in ABCB1 genotypes between AML patients and controls All 100 patients with de novo AML and the 400 healthy controls were successfully genotyped for the five ABCB1 SNPs. No significant difference in genotype frequencies was found between patients and the reference population (Table 2) , and the distribution of four of the SNPs (G1199A, C1236T, G2677T/A and C3435T) were in Hardy-Weinberg equilibrium. However, for A1308T, only the A/A genotype was found among these 500 individuals. In addition, all patients but one were successfully analyzed for FLT3-ITD and NPM1 mutations (Table 1) . No significant difference in distribution of ABCB1 genotypes were found depending on FLT3-ITD or NPM1 mutation status (data not shown).
NPM1 mutation, but not FLT3-ITD or ABCB1 genotype, correlates with higher rate of CR Of the 100 AML patients included, 72 patients achieved CR, 24 did not reach CR and 3 could not be evaluated. We could not find any significant correlation between the different ABCB1 SNPs and the response rate in the AML patients. Neither were there any significant differences in FLT3 status between patients who achieved CR and those who did not. However, NPM1 mutations correlated significantly with CR rates (P ¼ 0.04). Of the 46 patients who carried mutated NPM1, 39 (85%) achieved CR, whereas only 33 of the 50 patients (66%) with wild type reached CR.
The ABCB1 SNPs C1236T and G2677T, as well as FLT3-ITD/ NPM1, influence the long-term survival of AML patients In accordance with previous studies, 31 our data indicated that NPM1-positive and FLT3-ITD-negative patients showed better overall survival than the other patients (Figure 1a , P ¼ 0.06). As only one patient had the 1199A/A genotype, we compared the overall survival of patients with the 1199 G/G genotype versus all patients with G/A and A/A genotypes; this comparison showed borderline significance (Figure 1b , P ¼ 0.06). The estimated mean survival for patients with the 1199G/G and G/A genotypes was 1.2 and 0.9 years, respectively, whereas the patient carrying the A/A genotype survived for 16 days. For C1236T, patients carrying the C/C genotype had a significantly shorter survival than those with other genotypes (Figure 1c , P ¼ 0.03). The mean survival was 0.7, 1.3 and 1.8 years for patients with the C/C, C/T and T/T genotypes, respectively. The 2677A allele was only present in four patients: two were heterozygous for G/A and two heterozygous for T/A, and they were excluded from analysis because of the low frequency. Patients carrying the Abbreviations: AML, acute myeloid leukemia; SNP, single-nucleotide polymorphism. All genotypes are in Hardy-Weinberg equilibrium and there were no significant differences in genotype frequencies between the two groups (P40.05).
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H Gréen et al wild-type 2677G/G had a significantly shorter survival than those with other genotypes (Figure 1d , P ¼ 0.02). The mean survival time of patients with G/G, G/T and T/T genotype of SNP G2677T/A was 0.7, 1.2 and 1.7 years, respectively.
The C3435T genotype did not significantly correlate with survival ( Figure 1e , P40.05) and excluding patients who were transplanted from the analysis had minor impact on the statistics (data not shown). Figure 1 The overall survival of AML patients depending on FLT3 and NPM1 mutation status or ABCB1 genotype. Survival was compared between (a) patients carrying a NPM1 mutation and FLT3-ITD wild type versus the other patients, and patients carrying the different genotypes of the ABCB1 SNPs (b) G1199A G/G vs G/A&A/A, (c) C1236T, (d) G2677T and (e) C3435T. The P-values represent the comparison of the genotypes by log-rank tests.
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In a multivariate Cox regression model the influence of age, NPM1 mutation, FLT3-ITD and the SNPs in the ABCB1 gene on overall survival was investigated. However, the SNPs C1236T and G2677T are present in linkage disequilibrium 16, 32 that is, if the patient has the wild-type allele of one of the SNPs there is a high probability that the patient also has the wild-type variant of the other, and the effect of these SNPs could not be distinguished from each other. We therefore conducted two separate Cox regression analyses, one for each of these SNPs, to determine the influence of the separate genotypes on survival (Table 3 ). Both the ABCB1 SNPs C1236T and G2677T had a significant impact on survival in these models: the hazard ratios for patients carrying the 1236T/T and 2677T/T genotypes were 0.24 and 0.22 as compared with patients having the 1236C/C and 2677G/G genotypes, respectively. NPM1 and FLT3-ITD were independent factors for survival in the C1236T model and there was also an indication in the G2677T model. The hazard ratios for NPM1 and FLT3-ITD were 0.6 and 1.7-1.9, respectively (Table 3) . Age was a significant variable in both models. G1199A lost its significance in the multivariate models probably because of multiple testing and the low allele frequency.
The ABCB1 SNPs influence the cytotoxicity of leukemic cells in vitro We tested the in vitro sensitivity of leukemic cells from 56 patients to chemotherapeutic drugs commonly used in the treatment of AML. As it has previously been shown that FLT3-ITD has an impact on the cells' susceptibility to cytotoxic stimuli, 33 the effect of the ABCB1 SNPs were investigated in cells from patients with wild-type FLT3, in which the resistance is not affected by the FLT3-ITD. The susceptibility of leukemic cells from patients with the 1199G/A, 1236T/T, 2677T/T and 3435T/T genotypes of the ABCB1 SNPs was compared with the susceptibility of cells from all the other patients ( Figure 2) . We chose to compare the genotype that gave the best survival in the survival analysis with the rest, as they might show the lowest cell survival and therefore lowest variability in a viability assay. For the SNPs C1236T and G2677T, there was a significant difference in the in vitro survival of cells exposed to mitoxantrone (P ¼ 0.02), and borderline significance for cells exposed to etoposide and daunorubicin (P ¼ 0.07-0.09). Cells of different genotypes did not differ in their sensitivity to the cytotoxic effects of cytarabine. The SNPs G1199A and C3435T did not affect the in vitro cytotoxicity; however, as only three of the patients from whom the leukemic cells were isolated were heterozygous for G1199A, cautious interpretation is warranted.
Discussion
In this study we show that normal karyotype AML patients with the C/C and G/G genotype of ABCB1 SNPs C1236T and G2677T had a significantly shorter overall survival than the other patients with normal karyotype AML. We also found an indication that the genetic variant G1199A influenced the survival. In a multivariate analysis the SNPs 1236C/C and 2677G/G were shown to be independent prognostic factors, along with FLT3-ITD, NPM1 and age. The SNPs G2677T and C1236T were also shown to influence the in vitro resistance of isolated leukemic cells from patients against several P-glycoprotein substrates.
Our results indicate that ABCB1 genotype has potential as a prognostic marker for predicting survival in AML patients with normal karyotype. Hence, the group of patients with intermediate risk, and in whom treatment response is uncertain, might be diminished further by ABCB1 genotyping. A previous publication by Illmer et al. that investigated the ABCB1 SNPs C1236T, G2677T/A and C3435T in unselected Caucasian AML patients (n ¼ 405) showed that patients with the wild-type variants of C1236T, G2677T/A and C3435T (1236C/C, 2677G/G and 3435C/C) had shorter overall survival and a greater risk of relapse than patients with other genotypes. 19 Our results support these findings in normal karyotype de novo AML, as patients carrying the C/C or G/G genotypes of C1236T and G2677T have shorter overall survival in our study. In contrast, a study by van der Holt et al. 22 (n ¼ 150) showed no difference in CR, For G2677T/A the A-allele was excluded from the analysis because of low frequency.
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H Gréen et al relapse-free survival or disease-free survival for the same ABCB1 SNPs. The population studied by van der Holt et al. was older than 60 years and came from a clinical trial investigating the P-glycoprotein inhibitor PSC-833; which might explain the discrepancy between their results and those reported by us and Illmer et al. 19 In younger patients with relapsed AML (n ¼ 30), van den Heuvel-Eibrink et al. 21 have shown that homozygosity for G2677T (G/G and T/T vs G/T) was associated with shorter relapse-free periods and shorter overall survival. Moreover, two studies on Korean populations with AML have been published, where Hur et al. 20 could not demonstrate any significant difference in terms of survival between ABCB1 C3435T genotypes whereas Kim et al. 34 reported that patients carrying 2677G/G and 3435C/C had a greater chance of CR and longer eventfree survival, but not longer overall survival. However, the impact of the ABCB1 SNPs might differ in the different ethnic populations. The SNP G1199A was not investigated in any of the other studies, but we found an indication that this SNP might have an impact on survival, although this has to be studied further. Our results agree with those of a small study on ovarian cancer, where heterozygous patients (1199G/A) showed clinical resistance to paclitaxel-carboplatin treatment and a shorter progression-free survival. 25 Our results also concur with in vitro data on this SNP showing that cells expressing the 1199A variant have increased resistance to other chemotherapeutic agents such as doxorubicin, vincristine and vinblastine. 35, 36 The effect of C1236T and G2677T/A on survival remained significant in multivariate analysis and-together with age, NPM1 and FLT3 status-these SNPs seem to be important variables for therapeutic response in AML. Noteworthy is that the hazard ratios of these ABCB1 SNPs had higher values than NPM1 and FLT3 in this population. This would indicate that the ABCB1 genotype has relatively strong impact on survival. We also found that the ABCB1 SNPs were not a major factor in genetic susceptibility to AML, which is in accordance with previous findings. 37 It is noteworthy that neither our study nor any of the other studies in Caucasians showed a correlation between the ABCB1 genotypes and CR. However, we showed that NPM1 mutations but not FLT3-ITD is a positive prognostic marker for CR. This is in accordance with recent data showing that NPM1 mutations predict early response parameters such as CR and early blast cell clearance. 38 Our clinical observation of the effect of the ABCB1 SNPs C1236T and G2677T is also supported by the in vitro cytotoxicity data: leukemic cells from patients with the best prognosis (that is, those with 1236T/T and 2677T/T genotypes) had a significantly lower in vitro survival. Daunorubicin, etoposide and mitoxantrone are known ABCB1 substrates in vitro, 39, 40 whereas the pyridine analog cytarabine are believed not to be transported by P-glycoprotien. 41 Our in vitro data suggest that only the drugs that are known as P-glycoprotein substrates are affected by the ABCB1 genotypes. The functional consequences of these ABCB1 SNPs have not been extensively studied in vitro for these substrates. In contrast to our study, Schaefer et al. showed in membrane vesicle preparations that, as compared with the wild-type variant (2677G), the maximum transport velocities of vincristine were significantly increased by 1.5-and threefold for the 2677T and the 2677A variants, respectively. 42 This would indicate a higher resistance for the 2677T variant than for 2677G, which is in contradiction to the lower survival we observed in isolated leukemic cells from patients homozygous for T in this position. In another study using Hela cells, the wild type showed a slightly Figure 2 The in vitro sensitivity of leukemic cells from FLT3-ITD wild-type patients to chemotherapeutic drugs commonly used in the treatment of AML and its correlation to ABCB1 SNPs (a) C1236T and (b) G2677T. The survival of the leukemic cells from patients carrying the 1236 or 2677 T/T genotypes was compared with the survival of cells from the other patients. Abbreviations: Mit, mitoxantrone (n ¼ 29); Eto, etoposide (n ¼ 32), Ara-C, cytarabine (n ¼ 33) and Dnr, daunorubicin (n ¼ 33).
ABCB1 genotypes in AML H Gréen et al higher efflux of paclitaxel than the Ser893 variant (2677T), 43 in agreement with our results. In contrast, transport of other substrates such as verapamil, vinblastine, calcein-AM, prazosin, bisantrene, forskolin, digoxin and cyclosporin A was not affected by G2677T/A or C3435T variants of P-glycoprotein; however, for each substrate only one concentration was tested. 32, 43, 44 In conclusion our findings suggest that certain ABCB1 SNPs (for example, C1236T and G2677T) affect the survival of AML patients with normal karyotype after chemotherapy and might provide useful information for treatment strategies and individualized chemotherapy. Our data show that patients carrying the 1236T/T or 2677T/T genotypes benefit from standard AML treatment with anthracyclines and cytarabine, and might be considered as low-risk patients. Conversely, patients carrying the 1236C/C and 2677G/G genotypes have a poorer prognosis when treated according to standard regimes and should be considered for allogeneic bone marrow transplantation or chemotherapy containing fludarabine and cytarabine or second-generation nucleoside analogs. If ABCB1 genotype proves to be a reliable prognostic marker, the number of intermediate risk patients might be decreased even further than today.
